Cryo-Cell International, Inc.
CCEL
$3.41
-$0.11-3.13%
AMEX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.56% | -1.31% | -0.29% | 1.10% | 2.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.56% | -1.31% | -0.29% | 1.10% | 2.33% |
| Cost of Revenue | 46.78% | 49.43% | -39.23% | -36.68% | -35.91% |
| Gross Profit | -18.32% | -17.83% | 23.20% | 24.20% | 26.43% |
| SG&A Expenses | -1.24% | -2.13% | 4.03% | 7.75% | 6.27% |
| Depreciation & Amortization | 15.76% | 55.40% | 34.31% | 17.90% | -26.73% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.72% | 10.24% | -14.26% | -11.66% | -13.11% |
| Operating Income | -95.24% | -87.27% | 3,119.40% | 1,629.54% | 526.09% |
| Income Before Tax | -210.11% | -183.35% | 111.76% | 113.01% | 118.45% |
| Income Tax Expenses | -105.61% | -96.16% | 156.31% | 154.08% | 159.59% |
| Earnings from Continuing Operations | -2,169.18% | -704.15% | 94.70% | 98.16% | 101.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,169.18% | -704.15% | 94.70% | 98.16% | 101.32% |
| EBIT | -95.24% | -87.27% | 3,119.40% | 1,629.54% | 526.09% |
| EBITDA | -75.96% | -67.26% | 734.21% | 671.33% | 2,743.18% |
| EPS Basic | -2,250.00% | -734.24% | 94.51% | 98.09% | 101.31% |
| Normalized Basic EPS | -186.43% | -176.36% | 341.50% | 338.70% | 212.46% |
| EPS Diluted | -3,775.00% | -776.51% | 93.40% | 97.26% | 100.78% |
| Normalized Diluted EPS | -188.56% | -178.54% | 329.81% | 323.88% | 209.69% |
| Average Basic Shares Outstanding | -0.25% | -0.76% | -1.40% | -2.06% | -2.56% |
| Average Diluted Shares Outstanding | -1.11% | -1.05% | -1.67% | -1.87% | -1.84% |
| Dividend Per Share | -70.00% | 60.00% | -- | -- | -- |
| Payout Ratio | -1.01% | -1.26% | -- | -- | -- |